Stocks News

LAST PRICE
61.4100
TODAY'S CHANGE (%)
Trending Down-1.9400 (-3.0624%)

Bid / Lots
61.0100/ 1
Ask / Lots
64.0000/ 1
Open / Previous Close
63.3600 / 63.3500
Day Range
Low 61.3100
High 63.7900
52 Week Range
Low 56.0500
High 100.7700
Volume
1,934,015
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW(R) 2024, from 11 hours ago by Business Wire
  11 hours ago by Business Wire
  Companies Mentioned: EXAS
  Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the company will present six abstracts on strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week(R) (DDW) 2024, May 18-21 in Washington, D.C. This includes data on Cologuard(R), the best-in-class non-invasive screening test for colorectal cancer in patients 45 and older at average risk, and the next-generation Cologuard test in development, Cologuard Plus(TM). Further details can be found at ddw.org.
- Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW(R) 2024, from 11 hours ago by Dow Jones
  11 hours ago by Dow Jones
  Companies Mentioned: EXAS
  MADISON, Wis.--(BUSINESS WIRE)--May 07, 2024--
  Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the company will present six abstracts on strategies and advancements for improving colorectal cancer screening rates and outcomes during Digestive Disease Week(R) (DDW) 2024, May 18-21 in Washington, D.C. This includes data on Cologuard(R) , the best-in-class non-invasive screening test for colorectal cancer in patients 45 and older at average risk, and the next-generation Cologuard test in development, Cologuard Plus(TM) . Further details can be found at ddw.org.
May 1, 2024
- Exact Sciences to Participate in May Investor Conference, from 6:00AM ET on Wednesday May 01, 2024 by Business Wire
  6:00AM ET on Wednesday May 01, 2024 by Business Wire
  Companies Mentioned: EXAS
  Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
- Exact Sciences to Participate in May Investor Conference, from 6:00AM ET on Wednesday May 01, 2024 by Dow Jones
  6:00AM ET on Wednesday May 01, 2024 by Dow Jones
  Companies Mentioned: EXAS
  MADISON, Wis.--(BUSINESS WIRE)--May 01, 2024--
  Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Apr 15, 2024
- Sector Update: Health Care Stocks Advance Premarket Monday, from 9:14AM ET on Monday Apr 15, 2024 by MT Newswires
  9:14AM ET on Monday Apr 15, 2024 by MT Newswires
  Companies Mentioned: EXAS, IBB, XLV, RARE, NMRA
  09:14 AM EDT, 04/15/2024 (MT Newswires) -- Health care stocks were advancing in premarket activity Monday as the Health Care Select Sector SPDR Fund (XLV) was up 0.6% and the iShares Biotechnology ETF (IBB) was 0.3% higher recently. Neumora Therape...

Today
- United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing, from 2 hours ago by MT Newswires
  2 hours ago by MT Newswires
  Companies Mentioned: UTHR
Yesterday
- Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing, from 4:47PM ET on Monday May 06, 2024 by MT Newswires
  4:47PM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: BMRN
- United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires
  4:43PM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: UTHR
- United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires
  4:43PM ET on Monday May 06, 2024 by MT Newswires
  Companies Mentioned: UTHR
May 4, 2024
- New Data for BioMarin's VOXZOGO(R) (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting, from 4:00PM ET on Saturday May 04, 2024 by PR Newswire
  4:00PM ET on Saturday May 04, 2024 by PR Newswire
  Companies Mentioned: BMRN
May 3, 2024
- United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing, from 4:39PM ET on Friday May 03, 2024 by MT Newswires
  4:39PM ET on Friday May 03, 2024 by MT Newswires
  Companies Mentioned: UTHR
- Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing, from 4:13PM ET on Friday May 03, 2024 by MT Newswires
  4:13PM ET on Friday May 03, 2024 by MT Newswires
  Companies Mentioned: MEDP
May 2, 2024
- UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating, from 11:35AM ET on Thursday May 02, 2024 by MT Newswires
  11:35AM ET on Thursday May 02, 2024 by MT Newswires
  Companies Mentioned: UTHR
- Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating, from 9:54AM ET on Thursday May 02, 2024 by MT Newswires
  9:54AM ET on Thursday May 02, 2024 by MT Newswires
  Companies Mentioned: UTHR
May 1, 2024
- Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing, from 4:59PM ET on Wednesday May 01, 2024 by MT Newswires
  4:59PM ET on Wednesday May 01, 2024 by MT Newswires
  Companies Mentioned: MEDP

Exact Sciences Corp
NASDAQ:EXASUnited States

Search Criteria

Today

Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW(R) 2024, from 11 hours ago by Business Wire

Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW(R) 2024, from 11 hours ago by Dow Jones

May 1, 2024

Exact Sciences to Participate in May Investor Conference, from 6:00AM ET on Wednesday May 01, 2024 by Business Wire

Exact Sciences to Participate in May Investor Conference, from 6:00AM ET on Wednesday May 01, 2024 by Dow Jones

Apr 15, 2024

Sector Update: Health Care Stocks Advance Premarket Monday, from 9:14AM ET on Monday Apr 15, 2024 by MT Newswires

Peers Headlines

Today

United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing, from 2 hours ago by MT Newswires

Yesterday

Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing, from 4:47PM ET on Monday May 06, 2024 by MT Newswires

United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires

United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing, from 4:43PM ET on Monday May 06, 2024 by MT Newswires

May 4, 2024

New Data for BioMarin's VOXZOGO(R) (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting, from 4:00PM ET on Saturday May 04, 2024 by PR Newswire

May 3, 2024

United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing, from 4:39PM ET on Friday May 03, 2024 by MT Newswires

Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing, from 4:13PM ET on Friday May 03, 2024 by MT Newswires

May 2, 2024

UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating, from 11:35AM ET on Thursday May 02, 2024 by MT Newswires

Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating, from 9:54AM ET on Thursday May 02, 2024 by MT Newswires

May 1, 2024

Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing, from 4:59PM ET on Wednesday May 01, 2024 by MT Newswires